mvjrМедицинский вестник Юга РоссииMedical Herald of the South of Russia2219-80752618-7876The Rostov State Medical University10.21886/2219-8075-2018-9-1-17-22mvjr-631Research ArticleОБЗОРЫREVIEWБезопасность и эффективность терапии современными препаратами идиопатического легочного фиброза (обзор литературы)Safety and efficiency of therapy with modern preparations of idiopathic pulmonary fibrosishttps://orcid.org/0000-0002-5129-0402СтрельцовЕ. А.Strel’tsovE. A.

Интерн 6 курса. Направление -  внутренние болезни.

lidigi@mail.ruКарагандинский государственный медицинский университетКазахстанKaraganda State Medical University, KaragandaKazakhstan201823032018911722Copyright © Стрельцов Е.А., 20182018Стрельцов Е.А.Strel’tsov E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medicalherald.ru/jour/article/view/631

В настоящем обзоре литературы рассмотрены вопросы эффективности и безопасности терапии ингибиторами тирозинкиназ и пирфенидоном при идиопатическом легочном фиброзе. Подробно освещены результаты рандомизированных исследований последних лет. Рассмотрена эффективность приема ингибиторов тирозинкиназ по следующим ключевым точкам исследований: годовой темп снижения жизненной емкости легких, тест 6-минутной ходьбы, качество жизни пациента и частота обострений. Системный поиск литературы проводился по базам данных Scopus, Web of Science, MedLine, elibrary и другим.

This review reviews the efficacy and safety of therapy with tyrosine kinase inhibitors and pyrphenidone in idiopathic pulmonary fibrosis. The results of randomized trials of recent years are described in detail. The efficacy of taking tyrosine kinase inhibitors at the following key research points is considered: the annual rate of decrease in vital capacity of the lung, a 6-minute walk test, the quality of life of the patient, and the frequency of exacerbations. Systematic literature search was carried out on the databases Scopus, Web of Science, MedLine, elibrary and others.

 

ингибиторы тирозинкиназидиопатический легочной фибрознинтеданибобзоринтерстициальные заболевания легких.tyrosine kinase inhibitoridiopathic pulmonary fibrosisnintedaniboverviewinterstitial lung diseaseReferencesBonella F., Stowasser S., Wollin L.. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib. // Drug Des Devel Ther. – 2015. - V.9. - P.6407-19. doi: 10.2147/DDDT.S76648 http://bmjopenrespres.bmj.com/content/4/1/e000192Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK et all. An offi cial ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fi brosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824. doi: 10.1164/rccm.2009-040GLRicheldi L., du Bois R.M., Raghu G., Azuma A., Brown K.K., Costabel U. et all. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. // N Engl J Med. – 2014. – V.370(22). – P.2071-82. doi: 10.1056/NEJMoa1402584Bonella F, Stowasser S, Wollin L. Idiopathic pulmonary fi bro-sis: current treatment options and critical appraisal of nintedanib. Drug Des Devel Th er. 2015;9:6407-19. doi: 10.2147/ DDDT.S76648http://www.nejm.org/doi/full/10.1056/NEJMoa1402584Hutchinson J, Fogarty A, Hubbard R, McKeever T et all. Global incidence and mortality of idiopathic pulmonary fi brosis: a systematic review. Eur Respir J. 2015;46(3):795– 806. doi: 10.1183/09031936.00185114Zhao H., Bian H., Bu X., Zhang S., Zhang P., Yu J. et all. Targeting of Discoidin Domain Receptor 2 (DDR2) Prevents Myofibroblast Activation and Neovessel Formation During Pulmonary Fibrosis. // Mol Ther. – 2016. – V.24(10). – P.1734-1744. doi: 10.1038/mt.2016.109Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D et al. Incidence and prevalence of idiopathic pulmonary fi brosis: review of the literature. Eur Respir Rev. 2012;21(126):355-61. doi: 10.1183/09059180.00002512https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112036/Richeldi L, Rubin AS, Avdeev S, Udwadia ZF, Xu ZJ. Idiopathic pulmonary fi brosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Med. 2015;13:237. doi: 10.1186/s12916-015-0495-0Hutchinson J., Fogarty A., Hubbard R., McKeever T.. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. // Eur Respir J. - 2015. – V.46(3). – P.795–806. doi: 10.1183/09031936.00185114Hinz B, Phan SH, Th annickal VJ, Prunotto M, Desmoulière A, Varga J et all. Recent developments in myofi broblast biology: paradigms for connective tissue remodeling. Am J Pathol. 2012;180(4):1340-55. doi: 10.1016/j.aj-path.2012.02.004http://erj.ersjournals.com/content/46/3/795.longBooth AJ, Hadley R, Cornett AM, Dreff s AA, Matthes SA, Tsui JL et.all. Acellular normal and fi brotic human lung matrices as a culture system for in vitro investigation. Am J Respir Crit Care Med. 2012;186(9):866-76. doi: 10.1164/ rccm.201204-0754OCRaghu G. , Wells A.U., Nicholson A.G., Richeldi L., Flaherty K.R., Le Maulf F. et all. Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria. // Am J Respir Crit Care Med. – 2017. – V.195(1). – P.78-85. doi: 10.1164/rccm.201602-0402OCValiathan RR, Marco M, Leitinger B, Kleer CG, Fridman R. Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metastasis Rev. 2012;31(1-2):295-321. doi: 10.1007/s10555-012-9346-zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214917/Leitinger B, Kwan AP. Th e discoidin domain receptor DDR2 is a receptor for type X collagen. Matrix Biol. 2006;25(6):355-64. DOI: 10.1016/j.matbio.2006.05.006Kim K.K., Sisson T.H., Horowitz J.C.. Fibroblast growth factors and pulmonary fibrosis: it's more complex than it sounds. // J Pathol. – 2017. – V.241(1). – P.6-9. doi: 10.1002/path.4825Maeyama M, Koga H, Selvendiran K, Yanagimoto C, Hanada S, Taniguchi E et all. Switching in discoid domain receptor expressions in SLUG-induced epithelial-mesenchymal transition. Cancer. 2008;113(10):2823-31. doi: 10.1002/ cncr.23900https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499705/Ackermann M, Kim YO, Wagner WL, Schuppan D, Valenzuela CD, Mentzer SJ et all. Eff ects of nintedanib on the mi-crovascular architecture in a lung fi brosis model. Angiogenesis. 2017;20(3):359-372. doi: 10.1007/s10456-017-9543-zVittal R., Zhang H., Han M.K., Moore B.B., Horowitz J.C., Thannickal V.J. et all. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases. // J Pharmacol Exp Ther. – 2007. – V.321(1). – P.35-44.Sato S, Shinohara S, Hayashi S, Morizumi S, Abe S, Okazaki H et all. Anti-fi brotic effi cacy of nintedanib in pulmonary fi brosis via the inhibition of fi brocyte activity. Respir Res. 2017;18(1):172. doi: 10.1186/s12931-017-0654-2http://jpet.aspetjournals.org/content/321/1/35.longMazzei ME, Richeldi L, Collard HR. Nintedanib in the treatment of idiopathic pulmonary fi brosis. Th er Adv Respir Dis. 2015;9(3):121-9. doi: 10.1177/1753465815579365Ackermann M., Kim Y.O., Wagner W.L., Schuppan D., Valenzuela C.D., Mentzer S.J. et all. Effects of nintedanib on the microvascular architecture in a lung fibrosis model. // Angiogenesis. – 2017. – V.20(3). – P.359-372. doi: 10.1007/s10456-017-9543-zZhao H , Bian H , Bu X, Zhang S Zhang P, Yu J et all. Targeting of Discoidin Domain Receptor 2 (DDR2) Prevents Myofi -broblast Activation and Neovessel Formation During Pulmonary Fibrosis. Mol Th er. 2016;24(10):1734-1744. doi: 10.1038/ mt.2016.109https://link.springer.com/article/10.1007%2Fs10456-017-9543-zHuang J, Maier C, Zhang Y, Soare A, Dees C, Beyer C et all. Nintedanib inhibits macrophage activation and ameliorates vascular and fi brotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis. 2017;76(11):1941-1948. doi: 10.1136/annrheumdis-2016-210823Cottin V.. The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis. // Expert Opin Drug Saf. – 2017. – V.16(7). – P.857-865. doi: 10.1080/14740338.2017.1338268Hostettler KE, Zhong J, Papakonstantinou E, Karakiulakis G, Tamm M, Seidel P et all. Anti-fi brotic eff ects of nintedanib in lung fi broblasts derived from patients with idiopathic pulmonary fi brosis. Respir Res. 2014;15:157. doi: 10.1186/ s12931-014-0157-3http://www.tandfonline.com/doi/abs/10.1080/14740338.2017.1338268?journalCode=ieds20Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Cos-tabel U et all. Effi cacy and safety of nintedanib in idiopathic pulmonary fi brosis. N Engl J Med. 2014;370(22):2071-82. doi: 10.1056/NEJMoa1402584Huang J., Maier C., Zhang Y., Soare A., Dees C., Beyer C. et all. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. // Ann Rheum Dis. – 2017. V.76(11). – P.1941-1948. doi: 10.1136/annrheumdis-2016-210823Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG Effi cacy of a tyrosine kinase inhibitor in idiopathic pulmonary fi brosis. N Engl J Med. 2011;365(12):1079-87. doi: 10.1056/NEJMoa1103690Sato S., Shinohara S., Hayashi S., Morizumi S., Abe S., Okazaki H. et all. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity. // Respir Res. – 2017. – V.18(1). – P.172. doi: 10.1186/s12931-017-0654-2Raghu G , Wells AU , Nicholson AG, Richeldi L, Flaherty KR, Le Maulf F et all. Eff ect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria. Am J Respir Crit Care Med. 2017;195(1):78-85. doi: 10.1164/ rccm.201602-0402OChttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603061/Cottin V. Th e safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fi brosis. Expert Opin Drug Saf. 2017;16(7):857-865. doi: 10.1080/14740338.2017.1338268Mazzei M.E., Richeldi L., Collard H.R.. Nintedanib in the treatment of idiopathic pulmonary fibrosis.// Ther Adv Respir Dis. – 2015. – V.9(3). – P.121-9. doi: 10.1177/1753465815579365Kim KK, Sisson TH, Horowitz JC. Fibroblast growth factors and pulmonary fi brosis: it’s more complex than it sounds. J Pathol. 2017;241(1):6-9. doi: 10.1002/path.4825http://journals.sagepub.com/doi/abs/10.1177/1753465815579365?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmedVittal R, Zhang H, Han MK, Moore BB, Horowitz JC, Th an-nickal VJ et al. Eff ects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fi brotic diseases. J Pharmacol Exp Th er. 2007;321(1):35-44Huang Z., Li H., Zhang Q., Tan X., Lu F., Liu H. et all. Characterization of preclinical in vitro and in vivo pharmacokinetics properties for KBP-7018, a new tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary fibrosis. // Drug Des Devel Ther. – 2015. – V.9. – P.4319-28. doi: 10.2147/DDDT.S83055Huang Z, Li H, Zhang Q, Tan X, Lu F, Liu H et all. Characterization of preclinical in vitro and in vivo pharmacokinetics properties for KBP-7018, a new tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary fi brosis. Drug Des Devel Th er. 2015;9:4319-28. doi: 10.2147/DDDT.S83055https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532346/Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A et all. Antifi brotic action of pirfenidone and predniso-lone: diff erent eff ects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fi bro-sis. Eur J Pharmacol. 2008;590(1-3):400-8. doi: 10.1016/j. ejphar.2008.06.046Hostettler K.E., Zhong J., Papakonstantinou E., Karakiulakis G., Tamm M., Seidel P. et all. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. // Respir Res. – 2014. – V.15. – P.157. doi: 10.1186/s12931-014-0157-3Liu Y, Lu F, Kang L, Wang Z, Wang Y. Pirfenidone attenuates bleomycin-induced pulmonary fi brosis in mice by regulating Nrf2/Bach1 equilibrium. BMC Pulm Med. 2017;17(1):63. doi:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4273482/1186/s12890-017-0405-7Richeldi L., Costabel U., Selman M., Kim D.S., Hansell D.M., Nicholson A.G.. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. // N Engl J Med. – 2011. –V.365(12). – P.1079-87. doi: 10.1056/NEJMoa1103690Lehtonen ST, Veijola A, Karvonen H, Lappi-Blanco E, Sormunen R, Korpela S et all. Pirfenidone and nintedanib modulate properties of fi broblasts and myofi broblasts in idiopathic pulmonary fi brosis. Respir Res. 2016;17:14. doi: 10.1186/s12931-016-0328-5http://www.nejm.org/doi/full/10.1056/NEJMoa1103690Ley B, Swigris J, Day BM, Stauff er JL, Raimundo K, Chou W et all. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017;196(6):756-761. doi: 10.1164/rccm.201701-0091OCHinz B., Phan S.H., Thannickal V.J., Prunotto M., Desmoulière A., Varga J. et all. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. // Am J Pathol. – 2012. – V.180(4). – P.1340-55. doi: 10.1016/j.ajpath.2012.02.004Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK et all. Eff ect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fi brosis. Lancet Respir Med. 2017;5(1):33-41. doi: 10.1016/S2213-2600(16)30326-5https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640252/Hui Ren, MD, Kai Wang, MD, Hao Yang, PHD, and Lingyun Gao, MD. Effi cacy and adverse events of pirfenidone in treating idiopathic pulmonary fi brosis. Saudi Med J. 2017; 38(9): 889–894. doi: 10.15537/smj.2017.9.19349Booth A.J., Hadley R., Cornett A.M., Dreffs A.A., Matthes S.A., Tsui J.L. et.all. Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. // Am J Respir Crit Care Med. – 2012. – V.186(9). – P.866-76. doi: 10.1164/rccm.201204-0754OCLancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD. Pirfenidone safety and adverse event management in idiopathic pulmonary fi brosis. Eur Respir Rev. 2017;26(146):170057. doi: 10.1183/16000617.0057-2017https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3530219/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3530219/Valiathan R.R., Marco M., Leitinger B., Kleer C.G., Fridman R.. Discoidin domain receptor tyrosine kinases: new players in cancer progression. // Cancer Metastasis Rev. – 2012. –V.31(1-2). – P.295-321. doi: 10.1007/s10555-012-9346-zValiathan R.R., Marco M., Leitinger B., Kleer C.G., Fridman R.. Discoidin domain receptor tyrosine kinases: new players in cancer progression. // Cancer Metastasis Rev. – 2012. –V.31(1-2). – P.295-321. doi: 10.1007/s10555-012-9346-zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351584/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351584/Leitinger B., Kwan A.P.. The discoidin domain receptor DDR2 is a receptor for type X collagen. // Matrix Biol. – 2006. – V.25(6). – P.355-64.Leitinger B., Kwan A.P.. The discoidin domain receptor DDR2 is a receptor for type X collagen. // Matrix Biol. – 2006. – V.25(6). – P.355-64.http://www.sciencedirect.com/science/article/pii/S0945053X06000588http://www.sciencedirect.com/science/article/pii/S0945053X06000588Maeyama M., Koga H., Selvendiran K., Yanagimoto C., Hanada S., Taniguchi E. et all. Switching in discoid domain receptor expressions in SLUG-induced epithelial-mesenchymal transition. // Cancer. – 2008. – V.113(10). – P.2823-31. doi: 10.1002/cncr.23900Maeyama M., Koga H., Selvendiran K., Yanagimoto C., Hanada S., Taniguchi E. et all. Switching in discoid domain receptor expressions in SLUG-induced epithelial-mesenchymal transition. // Cancer. – 2008. – V.113(10). – P.2823-31. doi: 10.1002/cncr.23900http://onlinelibrary.wiley.com/doi/10.1002/cncr.23900/abstract;jsessionid=E6E40ED667B5C303D44063FBD23E4320.f02t04http://onlinelibrary.wiley.com/doi/10.1002/cncr.23900/abstract;jsessionid=E6E40ED667B5C303D44063FBD23E4320.f02t04Nalysnyk L., Cid-Ruzafa J., Rotella P., Esser D. et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. // Eur Respir Rev. – 2012. - V.21(126). – P.355-61. doi: 10.1183/09059180.00002512Nalysnyk L., Cid-Ruzafa J., Rotella P., Esser D. et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. // Eur Respir Rev. – 2012. - V.21(126). – P.355-61. doi: 10.1183/09059180.00002512http://err.ersjournals.com/content/21/126/355.longhttp://err.ersjournals.com/content/21/126/355.longRicheldi L., Rubin A.S., Avdeev S., Udwadia Z.F., Xu Z.J.. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. // BMC Med. - 2015 V.13. – P.237. doi: 10.1186/s12916-015-0495-0Richeldi L., Rubin A.S., Avdeev S., Udwadia Z.F., Xu Z.J.. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. // BMC Med. - 2015 V.13. – P.237. doi: 10.1186/s12916-015-0495-0https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581420/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581420/Oku H., Shimizu T., Kawabata T., Nagira M., Hikita I., Ueyama A. et all. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. // Eur J Pharmacol. – 2008. – V.590(1-3). – P.400-8. doi: 10.1016/j.ejphar.2008.06.046Oku H., Shimizu T., Kawabata T., Nagira M., Hikita I., Ueyama A. et all. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. // Eur J Pharmacol. – 2008. – V.590(1-3). – P.400-8. doi: 10.1016/j.ejphar.2008.06.046http://www.sciencedirect.com/science/article/pii/S0014299908006389http://www.sciencedirect.com/science/article/pii/S0014299908006389Liu Y., Lu F., Kang L., Wang Z., Wang Y.. Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium. // BMC Pulm Med. – 2017. – V.17(1). – P.63. doi: 10.1186/s12890-017-0405-7Liu Y., Lu F., Kang L., Wang Z., Wang Y.. Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium. // BMC Pulm Med. – 2017. – V.17(1). – P.63. doi: 10.1186/s12890-017-0405-7https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395978/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395978/Ley B., Swigris J., Day B.M., Stauffer J.L., Raimundo K., Chou W. et all. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis. // Am J Respir Crit Care Med. – 2017. – V.196(6). – P.756-761. doi: 10.1164/rccm.201701-0091OCLey B., Swigris J., Day B.M., Stauffer J.L., Raimundo K., Chou W. et all. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis. // Am J Respir Crit Care Med. – 2017. – V.196(6). – P.756-761. doi: 10.1164/rccm.201701-0091OChttp://www.atsjournals.org/doi/abs/10.1164/rccm.201701-0091OC?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed&http://www.atsjournals.org/doi/abs/10.1164/rccm.201701-0091OC?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed&Hui Ren, MD, Kai Wang, MD, Hao Yang, PHD, and Lingyun Gao, MD. Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis. // Saudi Med J. -2017. – V.38(9). – P.889–894.doi: 10.15537/smj.2017.9.19349Hui Ren, MD, Kai Wang, MD, Hao Yang, PHD, and Lingyun Gao, MD. Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis. // Saudi Med J. -2017. – V.38(9). – P.889–894.doi: 10.15537/smj.2017.9.19349https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654021/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654021/Nathan S.D., Albera C., Bradford W.Z., Costabel U., Glaspole I., Glassberg M.K. et all. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. // Lancet Respir Med. – 2017. – V.5(1). – P.33-41. doi: 10.1016/S2213-2600(16)30326-5Nathan S.D., Albera C., Bradford W.Z., Costabel U., Glaspole I., Glassberg M.K. et all. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. // Lancet Respir Med. – 2017. – V.5(1). – P.33-41. doi: 10.1016/S2213-2600(16)30326-5http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(16)30326-5/fulltexthttp://www.thelancet.com/journals/lanres/article/PIIS2213-2600(16)30326-5/fulltextLehtonen S.T., Veijola A., Karvonen H., Lappi-Blanco E., Sormunen R., Korpela S. et all. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. // Respir Res. – 2016. – V.17. – P.14. doi: 10.1186/s12931-016-0328-5Lehtonen S.T., Veijola A., Karvonen H., Lappi-Blanco E., Sormunen R., Korpela S. et all. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. // Respir Res. – 2016. – V.17. – P.14. doi: 10.1186/s12931-016-0328-5https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743320/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743320/Raghu G., Collard H.R., Egan J.J., Martinez F.J., Behr J., Brown K.K. et all. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. // Am J Respir Crit Care Med. – 2011. – V.183(6). – P.788-824. doi: 10.1164/rccm.2009-040GLRaghu G., Collard H.R., Egan J.J., Martinez F.J., Behr J., Brown K.K. et all. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. // Am J Respir Crit Care Med. – 2011. – V.183(6). – P.788-824. doi: 10.1164/rccm.2009-040GLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450933/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450933/

The authors declare that there are no conflicts of interest present.